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Volume 58, Number 3 Abstracts 853study groups. Race notwithstanding, the Fistula First Breakthrough Initia-
tive targets 50% hemodialysis initiation with ﬁstulas, a benchmark beckoning
improvement in current ESRD care.Table. Hemodialysis initiation characteristics for ESRD patients in the
United States
White
(n ¼ 264,350)
Black
(n ¼ 148,808)
Hispanic
(n ¼ 69,830) P value
Mean age (SD) 65.9 (15.3) 58.4 (15.4) 58.0 (16.6) <.001
Female (%) 122,066 (41.2) 76,286 (48.1) 32,588 (42.9) <.001
AVF (%) 40,206 (15.2) 18,663 (12.5) 8,221 (11.8) <.001
AVG (%) 7,578 (2.9) 7,271 (4.9) 1,785 (2.6) <.001
IHC (%) 216,566 (81.9) 122,874 (82.6) 59,824 (85.7) <.001
AVF, Arteriovenous ﬁstula; AVG, arteriovenous graft; ESRD, end-stage
renal disease; IHC, intravenous hemodialysis.Thioglitazones Improve SFA Stenting Primary Patency Rates in
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Objectives: Low adiponectin levels are predictive of in-stent resteno-
sis for bare-metal coronary stents. Thioglitazone (TZD) treatment increases
adiponectin levels and decreases in-stent restenosis in coronary stents. Adi-
ponectin is secreted by vascular smooth muscle cells (VSMCs) and adipo-
cytes. Adiponectin promotes the quiescent phenotype of VSMCs leading
to less intimal hyperplasia. We hypothesize that diabetic patients on TZDs
have better superﬁcial femoral artery (SFA) stent primary patency rates
than diabetics not on TZDs.
Methods: Our institution maintains a database for SFA interventions.
Patients who underwent primary SFA stenting were identiﬁed. We excluded
patients undergoing concomitant tibial stenting. Student t-test, c2, and log
rank were used for the statistical analysis.
Results: We identiﬁed 108 diabetic patients who had a total of 118
limbs stented between January 2000 and December 2010. Twenty patients
were taking a TZD at the time of their SFA stent. Sixty-ﬁve percent of
TZD patients were treated for claudication vs 42% of patients not taking
TZDs (P ¼ .06). Patients taking TZDs were older (mean age, 69.1 vs 63;
P ¼ .03). No statistically signiﬁcant differences were identiﬁed for hyperten-
sion, hyperlipidemia, coronary artery disease, renal insufﬁciency, history of
smoking, and statin use. Survival analysis showed signiﬁcantly improved
primary patency for patients on TZDs (Fig; P ¼ .04). At 3 years, TZD
primary patencywas higher at 86% comparedwith 55% for diabetic patients not
on TZDs.
Conclusions: This translational research study demonstrates the novel
ﬁnding that diabetic patients on TZDs have better SFA stenting primaryFig.patency than diabetics not on TZDs. Improved primary patency leads to
less reinterventions and medical cost. Future work will evaluate the useful-
ness of adiponectin as a biomarker and therapeutic target.ACE Inhibitors Improve Outcomes in Percutaneous Infrainguinal
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Objectives: The favorable effects of angiotensin-converting-enzyme
(ACE) inhibitors on different aspects of cardiovascular disease and manage-
ment are not well understood. We evaluated the impact of ACE inhibitors
on postoperative outcomes in interventions for peripheral arterial disease
(PAD) by analyzing infrainguinal endovascular procedures from December
2004 to June 2012 in patients taking ACE inhibitors (AI) and not taking
ACE inhibitors (NAI).
Methods: Comparisons between AI and NAI were made using c2
tests and Kaplan-Meier survival curves. Multivariate regression analysis
was performed using the Cox proportional hazard model.
Results: A total of 149 patients (38.3% AI, 61.7% NAI) had 316 index
lesions (35.1% AI, 64.9% NAI). NAI were more likely to be female (66.7% vs
33.3%; P ¼ .001) and older at time of surgery (69.6 6 11.5 vs 74.0 6 12.4
years old; P¼ .002). NAI were more likely to have tissue loss than AI (84.6%
vs 72.3%; P ¼ .016). The mean follow-up time was 25.07 months. Primary
(at 18 months, 53.5% vs 47.7%; P ¼ .6) and secondary patency (at 18
months, 87.3% vs 81.7%; P ¼ .235) were equivocal in AI and NAI groups.
There was a strong trend favoring primary assisted patency in AI (at 18
months, 84.3% vs 70.7% in NAI; P ¼ .053) that did not reach statistical
signiﬁcance. Limb salvage was superior in AI (at 18 months, 97.8% vs
85.0% in NAI; P value ¼ .025). After controlling for diabetes, hypertension,
end-stage renal disease, hypercholesterolemia, coronary artery disease, TASC
score, smoking status, age, and tissue loss, AI usage was an independent posi-
tive predictor of limb salvage (P ¼ .007; relative risk, 0.082).
Conclusions: This data suggests that AI therapy is associated with
a beneﬁcial effect on the outcomes of percutaneous infrainquinal interven-
tions for PAD. Further understanding of the relationship between AIs
and limb salvage may help us improve the management of PAD.Why Wait? Concurrent Venogram During First Rib Resection for
Venous Thoracic Outlet Syndrome Is Safe and Efﬁcient
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Objectives: Surgical treatment of venous thoracic outlet syndrome
(VTOS) traditionally involves ﬁrst rib resection (FRR) followed by interval
venogram and balloon angioplasty. This approach can lead to an extended
need for anticoagulation and a separate anesthesia session. We present
outcomes for FRR with concurrent venogram.
Methods: Retrospective chart review was performed for consecutive
patients undergoing FRR with concurrent venogram for idiopathic VTOS
from 2/2007 to 2/2013. Venograms were performed immediately after
FRR with the arm in neutral and provocative positions. The primary
outcome was modiﬁcation of procedure following venogram. Secondary
outcomes were subclavian vein (SCV) patency, duration of anticoagulation,
and symptom relief.
Results: Twenty-four patients underwent FRR with venogram with
a mean follow-up time of 32.4 months. The mean age was 28.5 years (range,
17-52 years), and 14 (58.3%) were female. All were maintained on anticoagu-
lation prior to the procedure. Concurrent venogram resulted in modiﬁcation
of the procedure in 22 patients (91.7%). Of these, 21 patients (95.4%) under-
went balloon angioplasty, and one patient (4.5%) underwent further rib resec-
tion. Fifteen patients (62.5%) were discharged after the procedure with no
anticoagulation. For those receiving postoperative anticoagulation for persis-
tent minor thrombus, median time for anticoagulation duration was 5.6
months (range, 0.8-28.7 months). Two patients (8.3%) had postoperative
bleeding requiring thoracentesis or video-assisted thorascopic evaculation of
hemothorax. One patient (4.2%) suffered rethrombosis and was successfully
lysed open, resulting in a 2-year SCV primary patency of 95.8% and primary-
assisted patency of 100%. No patients required reoperation for VTOS and all
reported improvements in symptoms. Two patients (8.3%) underwent
prophylactic FRR on contralateral side for symptoms and SCV stenosis.
Conclusion: FRR with concurrent venogram is a safe procedure for
VTOS that allows for effective intraoperative modiﬁcation of the surgical
plan, resulting in excellent SCV patency, early cessation of anticoagulation,
and durable symptom relief.
